Lipocine Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
LPCN Nasdaq 2830 www.lipocine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lipocine Inc.

Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 - Jun 27th, 2025 5:28 am
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - Jun 26th, 2025 6:00 am
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - Jun 23rd, 2025 6:00 am
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - Jun 9th, 2025 6:00 am
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - May 22nd, 2025 6:00 am
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - May 14th, 2025 6:00 am
Lipocine: Q1 Earnings Snapshot - May 8th, 2025 6:12 am
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - May 8th, 2025 6:00 am
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - May 6th, 2025 6:00 am
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Mar 27th, 2025 10:03 am
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - Mar 26th, 2025 6:00 am
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Mar 13th, 2025 6:00 am
Lipocine Announces FDA Labeling Changes for Testosterone Products - Mar 12th, 2025 6:00 am
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - Feb 6th, 2025 6:00 am
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Dec 17th, 2024 6:00 am
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - Nov 18th, 2024 6:00 am
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - Nov 7th, 2024 6:00 am
Lipocine: Q3 Earnings Snapshot - Nov 7th, 2024 4:25 am
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Oct 31st, 2024 6:00 am
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - Oct 10th, 2024 6:00 am